Rehabilitation of cancer through oncogene inactivation

Trends in Molecular Medicine

Volumn 11, Issue 7, 2005, Pages 316-321

  Shachaf, Catherine M ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; EPIGENETICS; GENE ACTIVATION; GENE INACTIVATION; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE MYC; PHENOTYPE; REVIEW; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; DNA REPAIR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, MYC; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; STEM CELLS;

EID: 22144458273     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.05.003     Document Type: Review

References (66)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. A. Balmain The genetics and genomics of cancer Nat. Genet. 33 Suppl. 2003 238 244
3. S. Baylin, and T.H. Bestor Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1 2002 299 305
4. A.P. Feinberg The epigenetics of cancer etiology Semin. Cancer Biol. 14 2004 427 432
5. A.H. Lund, and M. van Lohuizen Epigenetics and cancer Genes Dev. 18 2004 2315 2335
6. R. Corvi Patterns of oncogene activation in human neuroblastoma cells J. Neurooncol. 31 1997 25 31
7. K.A. Blum Adult Burkitt leukemia and lymphoma Blood 104 2004 3009 3020
8. J.N. Davis The ETO (MTG8) gene family Gene 303 2003 1 10
9. S. Debernardi Understanding cancer at the chromosome level: 40 years of progress Eur. J. Cancer 40 2004 1960 1967
10. J.G. Jurcic Monitoring PML-RARα in acute promyelocytic leukemia Curr. Oncol. Rep. 5 2003 391 398
11. K. Metcalfe Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers J. Clin. Oncol. 22 2004 2328 2335
12. L.F. Peterson, and D.E. Zhang The 8;21 translocation in leukemogenesis Oncogene 23 2004 4255 4262
13. M.C. Wei Bcl-2-related genes in lymphoid neoplasia Int. J. Hematol. 80 2004 205 209
14. R. Ren Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia Nat. Rev. Cancer 5 2005 172 183
15. T. Reya Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
16. D.W. Felsher Cancer revoked: oncogenes as therapeutic targets Nat. Rev. Cancer 3 2003 375 380
17. D.W. Felsher Reversibility of oncogene-induced cancer Curr. Opin. Genet. Dev. 14 2004 37 42
18. S. Giuriato Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer Semin. Cancer Biol. 14 2004 3 11
19. B.J. Druker Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med. 344 2001 1038 1042
20. B.J. Druker Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
21. H. Hermeking The MYC oncogene as a cancer drug target Curr. Cancer Drug Targets 3 2003 163 175
22. D.W. Felsher Oncogenes as therapeutic targets Semin. Cancer Biol. 14 2004 1
23. R.N. Eisenman Deconstructing myc Genes Dev. 15 2001 2023 2030
24. N. Gomez-Roman Direct activation of RNA polymerase III transcription by c-Myc Nature 421 2003 290 294
25. J.H. Patel Analysis of genomic targets reveals complex functions of MYC Nat. Rev. Cancer 4 2004 562 568
26. C. Grandori The Myc/Max/Mad network and the transcriptional control of cell behavior Annu. Rev. Cell Dev. Biol. 16 2000 653 699
27. S. Pelengaris c-MYC: more than just a matter of life and death Nat. Rev. Cancer 2 2002 764 776
28. S. Pelengaris, and M. Khan The many faces of c-MYC Arch. Biochem. Biophys. 416 2003 129 136
29. D.R. Hipfner, and S.M. Cohen Connecting proliferation and apoptosis in development and disease Nat. Rev. Mol. Cell Biol. 5 2004 805 815
30. A. Wilson c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation Genes Dev. 18 2004 2747 2763
31. S. Pelengaris Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression Cell 109 2002 321 334
32. I. Flores Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia Oncogene 23 2004 5923 5930
33. S. Pelengaris Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis BMC Biol. 2 2004 26
34. D.W. Felsher, and J.M. Bishop Reversible tumorigenesis by MYC in hematopoietic lineages Mol. Cell 4 1999 199 207
35. M. Jain Sustained loss of a neoplastic phenotype by brief inactivation of MYC Science 297 2002 102 104
36. C.M. Shachaf MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer Nature 431 2004 1112 1117
37. A. Karlsson Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations Blood 101 2003 2797 2803
38. D. Marinkovic Reversible lymphomagenesis in conditionally c-MYC expressing mice Int. J. Cancer 110 2004 336 342
39. M. Cuendet Multiple myeloma regression mediated by bruceantin Clin. Cancer Res. 10 2004 1170 1179
40. M. Shafarenko Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in terminal myeloid differentiation Blood 103 2004 4259 4267
41. B.Y. Yung c-Myc-mediated expression of nucleophosmin/B23 decreases during retinoic acid-induced differentiation of human leukemia HL-60 cells FEBS Lett. 578 2004 211 216
42. S. Beer Developmental context determines latency of MYC-induced tumorigenesis PLoS Biol. 2 2004 e332
43. R.H. Blelloch Nuclear cloning of embryonal carcinoma cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 13985 13990
44. K. Hochedlinger Nuclear transplantation, embryonic stem cells and the potential for cell therapy Hematol. J. 5 Suppl. 3 2004 S114 S117
45. R.B. Boxer Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation Cancer Cell 6 2004 577 586
46. + cells in the mouse mammary gland represent an enriched progenitor cell population Dev. Biol. 245 2002 42 56
47. M. Al-Hajj Prospective identification of tumorigenic breast cancer cells Proc. Natl. Acad. Sci. U. S. A. 100 2003 3983 3988
48. S. Chunmeng, and C. Tianmin Skin: a promising reservoir for adult stem cell populations Med. Hypotheses 62 2004 683 688
49. A.A. Hardikar Generating new pancreas from old Trends Endocrinol. Metab. 15 2004 198 203
50. K. Pantel, and M. Otte Identification and characterisation of minimal residual disease in solid tumors Acta Med. Austriaca Suppl. 52 2000 8 12
51. W. Stock, and Z. Estrov Studies of minimal residual disease in acute lymphocytic leukemia Hematol. Oncol. Clin. North Am. 14 2000 1289 1305
52. R. Demicheli Tumour dormancy: findings and hypotheses from clinical research on breast cancer Semin. Cancer Biol. 11 2001 297 306
53. P.C. Kwok Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma J. Gastroenterol. Hepatol. 18 2003 450 455
54. V. Schirrmacher T-cell immunity in the induction and maintenance of a tumour dormant state Semin. Cancer Biol. 11 2001 285 295
55. J.W. Uhr, and R. Marches Dormancy in a model of murine B cell lymphoma Semin. Cancer Biol. 11 2001 277 283
56. P.P. Delsanto Analysis of a 'phase transition' from tumor growth to latency Phys. Rev. E. Stat. Phys. Plasmas Fluids Relat. Interdiscip. Topics 62 2000 2547 2554
57. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin. Oncol. 29 Suppl. 16 2002 15 18
58. R. Korah Integrin α5β1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow Cancer Res. 64 2004 4514 4522
59. E.J. Allenspach Notch signaling in cancer Cancer Biol. Ther. 1 2002 466 476
60. M.E. Valk-Lingbeek Stem cells and cancer; the polycomb connection Cell 118 2004 409 418
61. P. Cartwright LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism Development 132 2005 885 896
62. M.E. Hutchin Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle Genes Dev. 19 2005 214 223
63. G.N. Naumov Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy Cancer Res. 62 2002 2162 2168
64. I. Peroulis Antiangiogenic activity of endostatin inhibits C6 glioma growth Int. J. Cancer 97 2002 839 845
65. T. Udagawa Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy FASEB J. 16 2002 1361 1370
66. INK4a contributes to the outcome of cancer therapy Cell 109 2002 335 346